Researchers say it is important to carefully assess the timing of the start of corticosteroid treatment for Duchenne muscular dystrophy (DMD) in children and its potential association with disease outcomes. ... Read more
Deflazacort delays loss of ambulation (LOA) in Duchenne muscular dystrophy (DMD) patients by an average of 3.8 years more than standard of care corticosteroid treatments prednisone/prednisolone, post-hoc analyses of a Phase 3 clinical trial ... Read more
The U.S. Food and Drug Administration (FDA) yesterday announced the approval of the corticosteroid drug deflazacort (under the trade name Emflaza) for the treatment of Duchenne muscular dystrophy (DMD).
A technique called electrical impedance myography (EIM) can help detect muscle deterioration in people with Duchenne muscular dystrophy (DMD), according to a study published in the scientific journal Annals ... Read more
In a recent article titled “Therapeutic Strategy for Heart Failure in Becker Muscular Dystrophy” and published in the International Heart Journal, Dr. Koichi Kimura of the University of Tokyo ... Read more
More than 50 international experts came together last week in a workshop organized by the Parent Project Muscular Dystrophy (PPMD), to discuss bone health and osteoporosis in Duchenne muscular ... Read more
Duchenne muscular dystrophy (DMD) patients at more advanced disease stages, those reliant on wheelchairs, showed improved lung function when treated with deflazacort compared to prednisone, Marathon Pharmaceuticals reported in a presentation at the ... Read more
The effectiveness of Deflazacort (DFZ) against prednisone was tested in Duchenne muscular dystrophy (DMD) patients, and positive results were reported at the 2016 MDA Clinical Conference in Arlington, Virginia, in a presentation ... Read more